FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to experimental research in oncology, and can be used in development of methods for achieving antimetastatic effect. Method comprises paratamoral administration of immunomodulators to the tumor-bearing mice with melanoma B16 10 days after the transplantation. To do this alternately every other day add 0.3 ml of 150 IU Roncoleukin and 0.3 ml of 150 IU Ingarone for 8 days.
EFFECT: method provides complete inhibition of metastasis as compared to control group and also inhibits tumor growth.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR INHIBITION OF METASTASIS IN LUNGS | 2016 |
|
RU2632703C1 |
| METHOD FOR SUPPRESSING THE GROWTH OF B16 MELANOMA IN LABORATORY ANIMALS | 2022 |
|
RU2784443C2 |
| ANGIOGENESIS INHIBITOR, ANTI-ANGIOGENIC PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT OF MALIGNANT NEOPLASM | 2005 |
|
RU2287341C1 |
| ANTIMETASTATIC COMPOSITION | 2006 |
|
RU2308966C1 |
| PHARMACEUTICAL COMPOSITION BASED ON PALLADIUM COMPOUND | 2015 |
|
RU2613305C2 |
| ANTINEOPLASTIC AGENT | 2016 |
|
RU2623034C1 |
| CORRECTIVE AGENT FOR PARANEOPLASTIC DAMAGES AND TOXIC EFFECTS OF CYTOSTATIC POLYCHEMOTHERAPY | 2008 |
|
RU2385324C1 |
| MEANS FOR INHIBITING METASTASIS IN THE LUNGS | 2021 |
|
RU2762730C1 |
| ANTI-TUMOR AGENT | 2003 |
|
RU2240793C1 |
| METHOD OF COMBINATION THERAPY OF B16 MELANOMA IN METRONOMIC MODE IN EXPERIMENT | 2022 |
|
RU2792561C1 |
